Results 101 to 110 of about 1,762,642 (311)

Precision medicine in paediatrics: Progress and priorities

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain   +3 more
wiley   +1 more source

When meta‐analyses mislead: Promises and pitfalls in teratology counselling

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Meta‐analysis has become a central tool for evidence synthesis in clinical teratology, offering the promise of increased statistical power, earlier signal detection and consolidated guidance for teratology counselling. When conducted rigorously and interpreted carefully, pooled analyses can provide clinicians with a structured basis for risk ...
Yusuf Cem Kaplan, Nusret Uysal
wiley   +1 more source

Prevalence of pregnancy and birth outcomes following biologic exposure in immune‐mediated inflammatory diseases: A population‐based study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Almost 5% of pregnancies are affected by immune‐mediated inflammatory diseases (IMIDs). As treatments become available, understanding their use during pregnancy is important. We aimed to describe maternal, pregnancy and infant outcomes among IMID pregnancies exposed to biologic therapies. Methods Using the Merative™ MarketScan® Commercial Database,
Leah K. Flatman   +3 more
wiley   +1 more source

Evaluation of a two-tier preterm birth prevention service in a tertiary hospital in the United Kingdom: a retrospective cohort study

open access: yesBMC Pregnancy and Childbirth
Background Preterm birth is the most important cause of neonatal morbidity and mortality. Clinical guidelines recommend assessment of risk of preterm birth and implementation of interventions to reduce preterm birth risk through dedicated preterm birth ...
Michael Shea   +4 more
doaj   +1 more source

Emmetropisation following preterm birth [PDF]

open access: yes, 2002
Background/aims: Even in the absence of retinopathy of prematurity (ROP), premature birth signals increased risk for abnormal refractive development. The present study examined the relation between clinical risk factors and refractive development among ...
Wilkinson, A Graham   +7 more
core   +1 more source

The global extent of polypharmacy in neonatal intensive care: A systematic review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Pharmaceutical treatment in the neonatal intensive care unit (NICU) is challenging, with neonates often receiving multiple drugs during hospitalization. Given their physiological immaturity, polypharmacy raises concerns about potential adverse effects, drug–drug interactions and the risk of supratherapeutic or subtherapeutic treatment.
Mia Finserås Bretun   +6 more
wiley   +1 more source

Variation in risk factors and timing of birth for different types of preterm birth: A historical cohort study

open access: yesActa Obstetricia et Gynecologica Scandinavica
Introduction The aim of this study was to investigate the risk factors and timing of birth for different types of preterm birth, including iatrogenic preterm birth, spontaneous preterm birth, and preterm prelabor rupture of membranes across health ...
Vanessa El‐Achi   +10 more
doaj   +1 more source

The placental transfer of nirmatrelvir using the ex vivo human placental perfusion model

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Nirmatrelvir is an effective therapeutic option for COVID‐19 infection and is often administered after symptom onset in pregnant individuals, but few data are available on the associated fetal exposure. The placental perfusion model evaluates maternal–fetal drug transfer across the human placenta and thus can determine fetal drug exposure.
Magdalene Zabek   +5 more
wiley   +1 more source

Population pharmacokinetics of levetiracetam in term neonates with hypoxic–ischemic encephalopathy and therapeutic hypothermia: The LEVNEONAT‐1 study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim This study aimed to describe the pharmacokinetics (PK) of levetiracetam (LEV) in term neonates treated for neonatal seizures secondary to hypoxic–ischemic encephalopathy (HIE). Methods Fifteen neonates were included and received a loading dose ranging from 30 to 60 mg/kg followed by eight maintenance doses corresponding to one‐fourth of the loading
Léo Mimram   +9 more
wiley   +1 more source

Are pregnancy‐ and lactation‐related eligibility criteria in cardiovascular clinical trials underpinned by drug safety data?

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim To quantify the prevalence of pregnancy‐, lactation‐ and reproductive potential‐related eligibility criteria in cardiovascular clinical trials and to evaluate whether they are supported by drug‐specific safety data. Methods We analysed randomized phase 3 and phase 4 cardiovascular clinical trials registered on ClinicalTrials.gov between 1 January ...
Jera Gurakuqi   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy